



SOUTH CAROLINA AIDS Drug Assistance Program (ADAP) Formulary

Revised July 2022

(alphabetical order by brand name within drug category)

Brand Name	Generic Name	Drug Class	Additional Information
HIV ANTIRETROVIRAL DRUGS			
Aptivus	tipranavir	Protease Inhibitor	
Biktarvy	bictegravir / emtricitabine / tenofovir alafenamide fumarate	Combination Treatment	Before prescribing, refer to the drug's full prescribing information.
Cabenuva (cabotegravir / rilpivirine)			<p>Additional Information for Cabenuva: Covered for ADAP IAP and MAP enrollees ONLY! Prior authorization <u>as a pharmacy benefit</u> may be required from the enrollee's health insurance provider prior to dispensing. Optional oral lead-in is coordinated through TheraCom Pharmacy at no cost. TheraCom General Phone: 1-877-654-7812 Cabenuva is available through a limited distribution network of pharmacies. SC ADAP enrollees should ensure they select one of the ADAP IAP Participating Pharmacies that is also on the ViiV Specialty Pharmacy Network list (currently, this includes Avita and CVS Specialty). SC ADAP <u>does not</u> cover the medical administration fee for the medication. The use of copay cards is <u>not allowed</u> for persons in SC ADAP.</p> <p>Clinical information: Patient has a diagnosis of HIV-1. Patient is currently virologically suppressed (HIV-1 RNA < 50 copies/mL) for at least 3 months. Patient is stable on a complete oral antiretroviral therapy (ART) regimen and there is a documented clinical reason for switching to Cabenuva. Patient does NOT have any of the following: 1) Baseline documented resistance to either cabotegravir (Vocabria) or rilpivirine (Edurant), 2) Prior virologic failure with ART containing integrase inhibitor or NNRTI, 3) Active hepatitis B virus (HBV) infection. Prior to initiating treatment with Cabenuva, consider oral lead-in should be used for at least 28 days to assess tolerability of cabotegravir and rilpivirine. For reauthorization, the patient remains virologically suppressed (HIV-1 RNA < 50 copies/mL) after initiation of treatment.</p>
Cimduo	lamivudine/tenofovir disoproxil fumarate	NRTI	Product carries a boxed warning for post-treatment acute exacerbations of hepatitis B.
Combivir	lamivudine / zidovudine	NRTI	
Complera	emtricitabine / rilpivirine / tenofovir disoproxil fumarate	Combination Treatment	Indicated as a complete regimen for treatment of HIV-1 infection: 1) In patients 12 years of age and older with no antiretroviral treatment history and with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy and 2) In certain virologically suppressed (HIV-1 RNA <50 copies/mL) patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen.
Delstrigo	doravirine / lamivudine/ tenofovir disoproxil fumarate	Combination Treatment	Product carries a boxed warning regarding the risk of post-treatment acute exacerbations of hepatitis B. Contraindicated when co-administered with drugs that are strong cytochrome P450 3A enzyme inducers (decreases in doravirine plasma concentrations may occur which may decrease the product's effectiveness). Refer to the package insert for concurrently administered drugs to avoid. Precautions include new onset or worsening renal impairment, risk of adverse reactions or loss of virologic response due to drug interactions, bone loss and mineralization defects, and Immune Reconstitution Syndrome.
Descovy	emtricitabine / tenofovir alafenamide	NRTI	



SOUTH CAROLINA AIDS Drug Assistance Program (ADAP) Formulary

Revised July 2022

(alphabetical order by brand name within drug category)

Brand Name	Generic Name	Drug Class	Additional Information
Dovato	dolutegravir / lamivudine	Combination Treatment	Dovato carries a Boxed Warning for patients co-infected with hepatitis B virus (HBV) and HIV-1. Prior to initiating treatment, patients should be tested for HBV infection. The emergence of HBV variants associated with resistance to lamivudine has been reported in HIV-1-infected patients who have received lamivudine-containing antiretroviral regimens in the presence of concurrent infection with HBV. In addition, severe exacerbations of HBV have been reported in patients co-infected with HIV-1 and HBV who have discontinued lamivudine.
Edurant	rilpivirine	NNRTI	
Emtriva	emtricitabine	NRTI	
Epivir	lamivudine	NRTI	
Epzicom	abacavir/ lamivudine	NRTI	Before adding an abacavir-containing medication to the drug regimen, refer to the drug's full prescribing information.
Evotaz	atazanavir / cobicistat	Combination Treatment	
Fuzeon	enfuvirtide	Fusion Inhibitor	Prior authorization required for an individual's first ADAP prescription for this drug.
Genvoya	elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide	Combination Treatment	
Intelence	etravirine	NNRTI	
ISENTRESS, ISENTRESS HD	raltegravir	Integrase Inhibitor	
Juluca	dolutegravir / rilpivirine	Combination Treatment	Clinical information regarding dolutegravir: At this point, women with HIV who wish to become pregnant and are currently receiving dolutegravir should be switched to a regimen with a more well-defined safety record in pregnancy. Women with HIV who are of childbearing age and are not interested in having children should be counseled about this information. Women who become pregnant while on dolutegravir need to discuss options with their HIV providers.
Kaletra	lopinavir / ritonavir	Protease Inhibitor	
Lexiva	fosamprenavir	Protease Inhibitor	
Norvir	ritonavir	Protease Inhibitor	



SOUTH CAROLINA AIDS Drug Assistance Program (ADAP) Formulary

Revised July 2022

(alphabetical order by brand name within drug category)

Brand Name	Generic Name	Drug Class	Additional Information
Odefsey	emtricitabine / rilpivirine / tenofovir alafenamide fumarate	Combination Treatment	Indicated as a complete regimen for treatment of HIV-1 infection in patients 12 years of age and older as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to individual components of Odefsey.
Pifeltro	doravirine	NNRTI	Contraindicated when co-administered with drugs that are strong cytochrome P450 3A enzyme inducers. Decreases in doravirine plasma concentrations may occur which may decrease the product's effectiveness. Refer to the package insert for concurrently administered drugs to avoid. Other warnings and precautions include risk of adverse reactions or loss of virologic response due to drug interactions and Immune Reconstitution Syndrome.
Prezcobix	darunavir / cobicistat	Combination Treatment	
Prezista	darunavir	Protease Inhibitor	
Retrovir	zidovudine	NRTI	
Reyataz	atazanavir	Protease Inhibitor	
Rukobia	fostemsavir	GP120 Attachment Inhibitor	
Selzentry	maraviroc	CCR5 Co-Receptor Antagonist	Prior authorization required for an individual's first ADAP prescription for this drug.
Stavudine	stavudine	NRTI	
Stribild	elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate	Combination Treatment	
Sustiva	efavirenz	NNRTI	
Symfi, Symfi Lo	efavirenz / lamivudine / tenofovir disoproxil fumarate	Combination Treatment	Product carries a boxed warning for post-treatment acute exacerbations of hepatitis B.
Symtuza	darunavir / cobicistat / emtricitabine / tenofovir alafenamide	Combination Treatment	



SOUTH CAROLINA AIDS Drug Assistance Program (ADAP) Formulary

Revised July 2022

(alphabetical order by brand name within drug category)

Brand Name	Generic Name	Drug Class	Additional Information
Tivicay	dolutegravir	Integrase Inhibitor	Clinical information regarding dolutegravir: At this point, women with HIV who wish to become pregnant and are currently receiving dolutegravir should be switched to a regimen with a more well-defined safety record in pregnancy. Women with HIV who are of childbearing age and are not interested in having children should be counseled about this information. Women who become pregnant while on dolutegravir need to discuss options with their HIV providers.
Triumeq	abacavir / dolutegravir / lamivudine	Combination Treatment	Before adding an abacavir-containing medication to the drug regimen, refer to the full prescribing information. Clinical information regarding dolutegravir: At this point, women with HIV who wish to become pregnant and are currently receiving dolutegravir should be switched to a regimen with a more well-defined safety record in pregnancy. Women with HIV who are of childbearing age and are not interested in having children should be counseled about this information. Women who become pregnant while on dolutegravir need to discuss options with their HIV providers.
Trizivir	abacavir / lamivudine / zidovudine	NRTI	Before adding an abacavir-containing medication to the drug regimen, refer to the drug's full prescribing information.
Trogarzo	Ibalizumab-uiyk	CD4 post-attachment HIV-1 inhibitor	Prior authorization is required for this medication. To initiate the process, please go to the website listed below and click on "Download Enrollment Form." https://www.trogarzo.com/hcp/patient-support/
Truvada	emtricitabine / tenofovir disoproxil fumarate	NRTI	
Tybost	cobicistat	Boosting Agent	Tybost should not be used with cobicistat-containing drugs such as Evotaz, PrezcoBix, or Stribild. Tybost in combination with lopinavir/ritonavir or regimens containing ritonavir is not recommended due to similar effects of Tybost and ritonavir on CYP3A. Refer to the product's full prescribing information at https://www.gilead.com/science-and-medicine/medicines
Viracept	nelfinavir	Protease Inhibitor	
Viramune	nevirapine	NNRTI	
Viramune XR	nevirapine	NNRTI	
Viread	tenofovir	NRTI	
Ziagen	abacavir	NRTI	Before adding abacavir to the drug regimen, refer to the drug's full prescribing information.



SOUTH CAROLINA AIDS Drug Assistance Program (ADAP) Formulary

Revised July 2022

(alphabetical order by brand name within drug category)

Brand Name	Generic Name	Drug Class	Additional Information
OPPORTUNISTIC AND CO-INFECTION DRUGS			
Acyclovir	acyclovir	Antiviral	
Amoxicillin	amoxicillin	Antibiotic	
Augmentin	amoxicillin clavulanate	Antibiotic	
Cipro	ciprofloxacin, oral	Antibiotic	
Clarithromycin	clarithromycin	Antibiotic	
Cleocin	clindamycin	Antibiotic	
Clotrimazole	clotrimazole	Antifungal	
Clotrimazole / betamethasone	clotrimazole / betamethasone topical	Antifungal	
Dapsone	dapsone	Antibiotic	
Diflucan	fluconazole	Antifungal	
Doxycycline monohydrate	doxycycline monohydrate	Antibiotic	
Doxycycline hyclate	doxycycline hyclate	Antibiotic	
Famciclovir	famciclovir	Antiviral	
Ketoconazole	ketoconazole tablets, topical	Antifungal	
Leucovorin	leucovorin	Opportunistic Infection	
Levaquin	levofloxacin, oral	Antibiotic	
Mepron	atovaquone	Antiprotozoal	
Metronidazole	metronidazole, oral	Antibiotic	
Moxifloxacin	moxifloxacin, oral	Antibiotic	
Nystatin	nystatin	Antifungal	
Nystatin/triamcin acetamide	nystatin / triamcinolone topical	Antifungal	
Relenza	zanamivir	Antiviral	
Ribavirin	ribavirin	Antiviral	
Sporanox	itraconazole	Antifungal	
Sulfadiazine	sulfadiazine	Antibiotic	
Sulfamethoxazole / trimethoprim	sulfamethoxazole / trimethoprim	Antibiotic	
Tamiflu	oseltamivir	Antiviral	
Trimethoprim	trimethoprim	Antibiotic	
Valcyte	valganciclovir	Antiviral	
Valtrex	valacyclovir	Antiviral	



SOUTH CAROLINA AIDS Drug Assistance Program (ADAP) Formulary

Revised July 2022

(alphabetical order by brand name within drug category)

Brand Name	Generic Name	Drug Class	Additional Information
Vfend	voriconazole, oral	Antifungal	
Zithromax	azithromycin	Antibiotic	
ANTICONVULSANTS			
Neurontin	gabapentin	Anticonvulsant	
ANTIDEPRESSANTS			
Amitriptyline	amitriptyline	Antidepressant	
Celexa	citalopram	Antidepressant	
Cymbalta	duloxetine	Antidepressant	
Effexor XR	venlafaxine	Antidepressant	
Lexapro	escitalopram	Antidepressant	
Paxil	paroxetine	Antidepressant	
Prozac	fluoxetine, daily formulation	Antidepressant	Prozac Weekly is not on the formulary.
Remeron	mirtazapine	Antidepressant	
Trazodone	trazodone	Antidepressant	
Wellbutrin XL, SR	bupropion	Antidepressant	
Zoloft	sertraline	Antidepressant	
ANTIEMETIC AGENTS			
Promethazine	promethazine	Antiemetic	
Zofran, Zofran ODT	ondansetron	Antiemetic	
ANTILIPEMIC AGENTS			
Crestor	rosuvastatin	Antilipemic Agent	
Pravastatin	pravastatin	Antilipemic Agent	
Zocor	simvastatin	Antilipemic Agent	
ANTITUBERCULOSIS AGENTS			
Myambutol	ethambutol	Antitubercular Agent	
Mycobutin	rifabutin	Antitubercular Agent	



SOUTH CAROLINA AIDS Drug Assistance Program (ADAP) Formulary

Revised July 2022

(alphabetical order by brand name within drug category)

Brand Name	Generic Name	Drug Class	Additional Information
HIV-ASSOCIATED LIPODYSTROPHY			
Egrifta SV	tesamorelin	Growth Hormone Releasing Factor	Prior authorization is required for this medication. To initiate the process, please go to the website listed below and click on "Download Egrifta SV Enrollment Form." https://hcp.egriftasv.com/
ORAL STEROIDS			
Prednisone	prednisone, oral	Steroid	
SMOKING CESSATION PRODUCTS			
South Carolina Tobacco Quitline: 1-800-QUIT-NOW			
Bupropion SR	bupropion SR tablets	Smoking Cessation	Tobacco users have a better chance at quitting with a treatment regimen inclusive of medications and counseling. Visit this webpage for information to assist patients with tobacco cessation: https://scdhec.gov/health/tobacco-use-prevention/tobacco-cessation
NicoDerm CQ	nicotine patch	Smoking Cessation	
Nicorette	nicotine polacrilex gum, lozenge	Smoking Cessation	
Nicotrol	nicotine inhaler, spray	Smoking Cessation	
Varenicline	varenicline tablets	Smoking Cessation	

SC ADAP DISPENSING GUIDELINES

SC ADAP Drug Formulary Recent Deletions:

- ~ Atripla (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) - discontinued in the U.S. for more than 1 year.
- ~ Invirase (saquinavir) - discontinued in the U.S. for more than 1 year.
- ~ Mytesi - Effective February 2022, Mytesi was removed from the drug formulary. Access to Mytesi may be available through enrollment in NapoCares. Click on this link for the NapoCares Enrollment Form:
<https://mytesi.com/wp-content/uploads/2022/03/mytesi-napocares-patient-support-program-enrollment-form.pdf>
- ~ Videx, Videx EC (didanosine) - discontinued in the U.S. for more than 1 year.
- ~ Vitekta (elvitegravir) - discontinued in the U.S. for more than 1 year.

Drug Coverage: A prescription is required for any ADAP formulary drug, regardless of whether the product is a prescription drug or an over-the-counter drug.

Generic Drugs: Generic formulations of ADAP formulary drugs are dispensed when determined as most cost-effective.

Quantity: Drug quantities of one-month supplies (as authorized by the prescriber) of ADAP formulary drugs are dispensed.

Prior Authorization: The physician should complete the SC ADAP pharmacy's prior authorization request form and then fax the form along with accompanying documentation to 412-787-9400 (fax). After approval of an ADAP client's initial prescription for a drug requiring prior
<https://www.pantherspecialty.com/sc-adap/>

ADAP Pharmacy Phone Number: 855-PANTHRX (803-728-3212)